Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial

医学 阿托伐他汀 养生 临床终点 血脂异常 人口 复视 内科学 外科 随机对照试验 Graves眼病 格雷夫斯病 疾病 环境卫生
作者
Giulia Lanzolla,Elena Sabini,Marenza Leo,Francesca Menconi,Roberto Rocchi,Angela Tindara Sframeli,Paolo Piaggi,Marco Nardi,Claudio Marcocci,Michele Marinò
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:9 (11): 733-742 被引量:80
标识
DOI:10.1016/s2213-8587(21)00238-2
摘要

Background A protective action of statins on development of Graves' orbitopathy suggests that statins might be used for treatment of the disease. We aimed to assess the efficacy of the addition of a statin, atorvastatin, to intravenous glucocorticoids (ivGCs) on Graves' orbitopathy outcomes in patients with hypercholesterolaemia. Methods We did a randomised, open-label, phase 2, adaptive, clinical trial at a single, tertiary, referral hospital in Pisa, Italy. Patients with moderate-to-severe, active Graves' orbitopathy, with a low-density lipoprotein cholesterol concentration between 2·97 and 4·88 mmol/L were eligible for inclusion. Patients were randomly assigned (1:1) in 11 blocks of eight, using a computer-based system, to the ST group or the NST group. The ST group received ivGCs (methylprednisolone 500 mg once a week for 6 weeks followed by 250 mg once a week for an additional six weeks) for 12 weeks and oral atorvastatin (20 mg once a day) for 24 weeks. The NST group only received the ivGC regimen. Patients were unmasked to group allocation; however, the ophthalmological investigator was masked to randomisation. The primary endpoint was the Graves' orbitopathy outcome (composite evaluation of exophthalmos, clinical activity score, eyelid aperture, and diplopia) at 24 weeks in the modified intention-to-treat (ITT) population (patients who attended the week 12 visit). Patients were considered responders when at least two of the following criteria were fulfilled in the most affected eye, without worsening in any of the same measures in both eyes: (1) reduction in exophthalmos of 2 mm or more, with no increase by 2 mm or more in the other eye; (2) reduction of clinical activity score by two or more points; (3) reduction in eyelid aperture by 2 mm or more, with no increase by 2 mm or more in the other eye; and (4) disappearance or improvement (change from constant to inconstant, intermittent, or absent, or from inconstant to intermittent or absent) of diplopia, and (5) improvement in visual acuity by 0·2 decimals or more. The trial is registered with EUDRACT, 2018-001317-33, and ClinicalTrials.gov, NCT03110848. Findings Between June 1, 2020, and Nov 30, 2020, 119 patients were screened for inclusion, of whom 88 (74%) patients were enrolled and randomly assigned to one of the two treatment groups (44 [50%] to the ST group and 44 [50%] to the NST group). Eight (9%) patients did not attend the 12 week visit; 80 (91%) patients (18 [23%] men and 62 [78%] women) were included in the modified ITT population (41 [51%] in the ST group and 39 [49%] in the NST group]. The proportion of Graves' orbitopathy composite evaluation responders at 24 weeks was higher in the ST group (21 [51%] of 41 patients) than the NST group (11 [28%] of 39 patients; attributable risk 0·23 [95% CI 0·02–0·44]; p=0·042). 26 adverse events occurred in 21 (24%) of 88 patients in the safety population. One (2%) of 44 patients in each group required treatment discontinuation, with no serious adverse events and no difference between groups. Interpretation Addition of oral atorvastatin to an ivGC regimen improved Graves' orbitopathy outcomes in patients with moderate-to-severe, active eye disease who were hypercholesterolaemic. Future phase 3 studies, which could potentially recruit patients regardless of low-density lipoprotein cholesterol concentration, are required to confirm this association. Funding Associazione Allievi Endocrinologia Pisana.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
牛姐完成签到,获得积分10
刚刚
刚刚
单纯草丛完成签到,获得积分10
刚刚
刚刚
刚刚
刚刚
华仔的应助被shichao采纳,获得10
刚刚
Jasper的应助被Z126采纳,获得10
刚刚
终梦发布了新的文献求助10
刚刚
GAP完成签到,获得积分10
刚刚
耀眼发布了新的文献求助10
刚刚
须臾完成签到,获得积分10
1秒前
1秒前
1秒前
1秒前
xxxxxx发布了新的文献求助10
1秒前
wh完成签到,获得积分10
1秒前
2秒前
2秒前
明天瘦到88完成签到 ,获得积分10
2秒前
漫柯完成签到,获得积分10
2秒前
3秒前
3秒前
dukejoe完成签到,获得积分10
3秒前
庾北瑶完成签到 ,获得积分10
3秒前
万能图书馆的应助被平常心采纳,获得10
3秒前
醒醒发布了新的文献求助10
3秒前
Eraser完成签到,获得积分10
3秒前
ililiiris发布了新的文献求助10
3秒前
失眠世平完成签到 ,获得积分10
4秒前
lucky完成签到,获得积分10
4秒前
4秒前
pierniao发布了新的文献求助10
4秒前
柚子完成签到 ,获得积分10
4秒前
4秒前
赘婿的应助被科研小白采纳,获得10
5秒前
李健的小迷弟的应助被zoya采纳,获得10
5秒前
Maestro_S发布了新的文献求助50
5秒前
古古怪界丶黑大帅完成签到,获得积分10
5秒前
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159663
求助须知:如何正确求助?哪些是违规求助? 9555211
关于积分的说明 21725494
捐赠科研通 7749713
什么是DOI,文献DOI怎么找? 3427292
关于科研通互助平台的介绍 2552372
邀请新用户注册赠送积分活动 2471628